34.41
+2.32(+7.23%)
Currency In USD
| Previous Close | 32.09 |
| Open | 31.95 |
| Day High | 34.78 |
| Day Low | 31.83 |
| 52-Week High | 42.39 |
| 52-Week Low | 5.66 |
| Volume | 343,128 |
| Average Volume | 458,893 |
| Market Cap | 569.06M |
| PE | -2.95 |
| EPS | -11.66 |
| Moving Average 50 Days | 29.05 |
| Moving Average 200 Days | 14.58 |
| Change | 2.32 |
If you invested $1000 in RAPT Therapeutics, Inc. (RAPT) since IPO date, it would be worth $330.87 as of December 04, 2025 at a share price of $34.41. Whereas If you bought $1000 worth of RAPT Therapeutics, Inc. (RAPT) shares 5 years ago, it would be worth $179.29 as of December 04, 2025 at a share price of $34.41.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
RAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients with Food Allergies
GlobeNewswire Inc.
Oct 27, 2025 12:00 PM GMT
Trial initiation in food allergy follows promising results in Phase 2 trial in chronic spontaneous urticaria, another IgE-driven conditionRAPT seeks to develop a differentiated anti-IgE therapy for the many patients with food allergies SOUTH SAN FRAN
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock
GlobeNewswire Inc.
Oct 22, 2025 3:12 AM GMT
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for p
RAPT Therapeutics Announces Proposed Public Offering of Common Stock
GlobeNewswire Inc.
Oct 21, 2025 8:01 PM GMT
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for p